SCHEMBL313139

SCHEMBL313139

COC(=O)Cc1ccc(OC)cc1

nearest known ligand 0.69

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.69
CYP4F2 P78329 1/20 0.63
CYP4A11 Q02928 1/20 0.63
ALDH1A1 P00352 3/20 0.63
CYP3A4 P08684 1/20 0.62
CYP2C19 P33261 1/20 0.62
KLK7 P49862 3/20 0.61
KMT2A Q03164 1/20 0.58
ATM Q13315 1/20 0.58
TDP1 Q9NUW8 1/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
GAA P10253 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.58
KDM4E B2RXH2 1/20 0.57
POLB P06746 1/20 0.57
F2RL1 P55085 1/20 0.56
CTBP2 P56545 1/20 0.56
NPC1 O15118 1/20 0.56
PKM P14618 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19068066 0.94 HTT (0.62) HTTCYP4F2CYP4A11ALDH1A1CYP3A4
SCHEMBL31324194 0.91 ALDH1A1 (0.63) HTTCYP4F2CYP4A11ALDH1A1CYP3A4
SCHEMBL15522689 0.91 CYP4F2 (0.64) HTTCYP4F2CYP4A11ALDH1A1CYP3A4
SCHEMBL19926288 0.89 ALDH1A1 (0.65) HTTCYP4F2CYP4A11ALDH1A1SMN1; SMN2
SCHEMBL4113212 0.89 CYP4F2 (0.76) HTTCYP4F2CYP4A11ALDH1A1KMT2A
SCHEMBL38660993 0.89 HTT (0.56) HTTCYP4F2CYP4A11ALDH1A1CYP3A4
SCHEMBL3231393 0.88 HTT (0.63) HTTALDH1A1CYP3A4CYP2C19KLK7
SCHEMBL5431221 0.86 HTT (0.62) HTTALDH1A1CYP3A4CYP2C19KLK7
SCHEMBL20752944 0.84 CYP4F2 (0.59) HTTCYP4F2CYP4A11ALDH1A1CYP3A4
SCHEMBL2090275 0.84 CYP4F2 (0.59) HTTCYP4F2CYP4A11ALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 523 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022036033-A2 SOLID STATE FORMS OF AN ORGANIC COMPOUND SERVIER PHARMACEUTICALS, LLC (US) 2022-02-17 WO claimed
CN-113121726-A Composition containing bisimidazole photoinitiator and application thereof 优缔贸易(上海)有限公司 2021-07-16 CN claimed
CN-109096420-B Catalyst for olefin polymerization and olefin polymerization method 中国石油化工股份有限公司 2021-05-11 CN claimed
CN-108440299-A A method of preparing 4- nitro benzophenone class compounds 长沙理工大学 2018-08-24 CN claimed
EP-4721737-A1 USE OF PHARMACEUTICAL COMPOSITION COMPRISING COMPOUND HAVING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE FOR TREATING ANEMIA-RELATED DISEASES Scinnohub Pharmaceutical Co., Ltd. (CN) 2026-04-08 EP disclosed
US-20260034186-A1 ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS RIZUN NODARI (US) 2026-02-05 US disclosed
US-20260027136-A1 CANNABIS BASED THERAPEUTIC AND METHOD OF USE YUZU LV LLC (US) 2026-01-29 US disclosed
US-20260028316-A1 Biphenyl and Phenylpyridine Compounds PFIZER INC. (US) 2026-01-29 US disclosed
EP-4680226-A2 ACYLSULFONAMIDE KAT6A INHIBITORS Olema Pharmaceuticals, Inc. (US) 2026-01-21 EP disclosed
US-20260015327-A1 ACYLSULFONAMIDE KAT6A INHIBITORS OLEMA PHARMACEUTICALS INC (US) 2026-01-15 US disclosed
US-20250381196-A1 ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING KIDNEY DISEASES AND KIDNEY-RELATED DISEASES SHANGHAI YAO YUAN BIOTECHNOLOGY CO LTD (CN) 2025-12-18 US disclosed
US-12458653-B2 Cannabis based therapeutic and method of use YUZU LV LLC (US) 2025-11-04 US disclosed
EP-0109679-B1 PROCESS FOR THE SIMULTANEOUS PRODUCTION OF PHENYLACETATE ESTERS AND PHENYLACETALDEHYDES DENKI KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1985-08-14 EP disclosed
EP-0109679-A1 Process for the simultaneous production of phenylacetate esters and phenylacetaldehydes DENKI KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1984-05-30 EP disclosed
US-4328356-A Process for preparing esters of arylacetic acids from alpha-halo-alkylarylketones MONTEDISON S.P.A. (IT) 1982-05-04 US disclosed
US-4288364-A REACTING A 3-/2-HYDROXYIMINOACETYLAMINO/-2-OXOAZETIDINE WITH AN ORGANIC CARBONATE OR ACYL HALIDE CIBA-GEIGY CORPORATION (US) 1981-09-08 US disclosed
EP-0005507-A1 Process for the fragmentation of 3-(2-hydroxyimino-acetylamino)-2-oxo azetidin compounds and compounds obtained thereby CIBA-GEIGY AG (CH) 1979-11-28 EP disclosed
US-4060690-A COBALT CONTAINING CATALYST DYNAMIT NOBEL AKTIENGESELLSCHAFT (DT) 1977-11-29 US disclosed
US-4012392-A ANALGESICS, MORPHINE ANTAGONISTS ACF CHEMIEFARMA N.V. (NL) 1977-03-15 US disclosed
US-3974202-A CARBON MONOXIDE, BENZYL HALIDE AND AN ALCOHOL; COBALT OR IRON CARBONYL CATALYST DYNAMIT NOBEL AKTIENGESELLSCHAFT (DT) 1976-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260027136-A1 CANNABIS BASED THERAPEUTIC AND METHOD OF USE CNR1, CNR2, OPRM1 HTT 3522/4885CYP4F2 3638/4885CYP4A11 496/4885
US-20260015327-A1 ACYLSULFONAMIDE KAT6A INHIBITORS KAT6A, KAT2A, KAT6B HTT 1323/4885CYP4F2 3302/4885CYP4A11 2147/4885
US-20260034186-A1 ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS TRPV1, SOST, RUNX1 HTT 1114/4885CYP4F2 3258/4885CYP4A11 453/4885
US-20260028316-A1 Biphenyl and Phenylpyridine Compounds KAT2B, KAT2A, KAT6A HTT 305/4885CYP4F2 1818/4885CYP4A11 1400/4885
US-20250381196-A1 ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING KIDNEY DISEASES AND KIDNEY-RELATED DISEASES PHKA1, PHKA2, PHKG1 HTT 4483/4885CYP4F2 3529/4885CYP4A11 1845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.